MRK

NYSE·Healthcare·Drug Manufacturers - General·USA

Latest market price

131.07

+0.59+0.45%

Overview Short InterestFilings

MRKQT72Merck & Co., Inc.·NYSE

Overview Short InterestFilings

131.07+0.45%

News

Up 0.5% — Merck licenses experimental HIV pill to generic makers in 129 countries (reuters.com).

Medium confidence

Loading chart...

Screen all →

NVS-0.72%$155.01 AZN+0.59%$169.26 ABBV+0.95%$259.36 NVO+1.22%$48.77 AMGN+1.22%$376.04 JNJ+1.59%$263.40 GILD-1.18%$129.31 PFE-1.88%$24.54

Index	S&P 500, DJIA	P/E	36.82	EPS (ttm)	3.56	Insider Own	0.09%	Shs Outstand	2.47B	Perf Week	2.80%

Market Cap	323.72B	Forward P/E	13.65	EPS next Y	9.60	Insider Trans	-11.17%	Shs Float	2.47B	Perf Month	8.68%

Enterprise Value	367.51B	PEG	-	EPS next Q	2.27	Inst Own	76.71%	Short Float	1.19%	Perf Quarter	14.35%

Income	8.93B	P/S	4.94	EPS this Y	-21.56%	Inst Trans	-	Short Ratio	2.84	Perf Half Y	20.05%

Sales	65.59B	P/B	7.06	EPS next Y	244.71%	ROA	6.94%	Short Interest	29.36M	Perf YTD	24.52%

Book/sh	-	P/C	18.11	EPS next 5Y	37.00%	ROE	17.93%	52W High	131.74 -0.51%	Perf Year	56.07%

Cash/sh	-	P/FCF	22.93	EPS past 3/5Y	8.43% 21.23%	ROIC	13.34%	52W Low	76.66 70.98%	Perf 3Y	23.71%

Dividend Est.	3.40 (2.59%)	EV/EBITDA	19.57	Sales past 3/5Y	3.08% 9.35%	Gross Margin	75.91%	Volatility	2.09% 2.61%	Perf 5Y	68.00%

Dividend TTM	3.36 (2.56%)	EV/Sales	5.60	EPS Y/Y TTM	-47.33%	Oper. Margin	27.59%	ATR (14)	3.36	Perf 10Y	130.43%

Dividend Ex-Date	Jun 15, 2026	Quick Ratio	1.06	Sales Y/Y TTM	2.22%	Profit Margin	13.62%	RSI (14)	61.96	Recom	2.35

Dividend Gr. 3/5Y	5.42% 6.75%	Current Ratio	1.30	EPS Q/Q	-157.66%	SMA20	3.41%	Beta	0.20	Target Price	136.33

Payout	92.12%	Debt/Eq	1.07	Sales Q/Q	4.27%	SMA50	8.23%	Rel Volume	0.60	Prev Close	130.48

Employees	75,000	LT Debt/Eq	0.90	Earnings	Oct 29	SMA200	18.63%	Avg Volume	10.23M	Price	131.07

IPO Date	Jan 13, 1978	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.15% 2.77%	Net Debt/EBITDA	2.33	Volume	6,148,154	Change	0.45%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-13-26	Reiterated	Guggenheim	Buy	$140 → $145
Jul-13-26	Reiterated	BMO Capital	Outperform	$135 → $142
Jul-06-26	Reiterated	HSBC		$135 → $150
Jun-30-26	Reiterated	Jefferies	Hold	$148 → $141
Jun-02-26	Reiterated	Guggenheim	Buy	$122 → $140
May-01-26	Reiterated	Morgan Stanley	Equal Weight	$109 → $112
Mar-12-26	Reiterated	Wells Fargo	Overweight	$140 → $150
Feb-24-26	Reiterated	RBC Capital	Perform	$80 → $142
Feb-13-26	Reiterated	Deutsche Bank	Hold	$150
Feb-04-26	Reiterated	Goldman Sachs	Buy	$120 → $133

Company

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Ownership

Total institutional ownership76.71%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	65,593	64,926	64,168	60,115	59,283	48,704	41,518	39,121	42,294
Cost of Goods Sold Incl. D&A	15,802	18,195	15,193	16,126	17,411	13,626	13,618	12,016	13,509
Gross Profit	49,791	46,731	48,975	43,989	41,872	35,078	27,900	27,105	28,785
Selling, General and Administrative Excl. Other	9,544	10,731	10,100	9,884	9,669	9,403	8,569	9,455	10,102
Research and Development	22,149	12,514	17,938	30,531	13,548	12,245	13,397	9,724	9,752
Other Operating Expense	0	0	716	620	373	231	386	0	0
Operating Income	18,098	23,486	20,221	2,954	18,282	13,199	5,548	7,926	8,931
Interest Expense	1,043	1,357	1,271	1,146	962	806	831	893	772
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-5,425	-1,062	986	81	-876	1,486	1,146	138	542
Net Income Before Taxes	11,630	21,067	19,936	1,889	16,444	13,879	5,863	7,171	8,701
Income Taxes	2,696	2,804	2,803	1,512	1,918	1,521	1,340	1,565	2,508
Consolidated Net Income	8,935	18,254	17,117	365	14,519	13,049	7,067	9,843	6,220
Net Income From Continuing Operations	8,934	18,263	17,133	377	14,526	12,358	4,523	5,606	6,193
Net Income	8,935	18,254	17,117	365	14,519	13,049	7,067	9,843	6,220
EPS (Recurring)	3.56	7.30	6.76	0.14	5.73	5.16	2.79	3.84	2.40
EPS (Basic, Before Extraordinaries)	3.56	7.30	6.76	0.14	5.73	5.16	2.79	3.84	2.40
EPS (Diluted)	3.55	7.28	6.74	0.14	5.71	5.14	2.78	3.82	2.32
EBITDA	18,779	28,262	25,706	6,907	21,315	17,899	10,180	11,374	13,992
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	36.92	14.46	14.76	778.71	19.43	14.91	28.06	22.70	31.41
Price To Sales Ratio	4.94	4.06	3.93	4.73	4.74	3.98	4.75	5.69	4.47
Gross Margin	75.91	71.98	76.32	73.17	70.63	72.02	67.20	69.29	68.06
Operating Margin	27.59	36.17	31.51	4.91	30.84	27.10	13.36	20.26	21.12
Net Margin	13.62	28.12	26.68	0.61	24.49	26.79	17.02	25.16	14.71
Shares Outstanding	2,472	2,502	2,532	2,607	2,532	2,530	2,530	2,565	2,593
Market Capitalization	324,005	263,361	251,883	284,215	280,925	193,899	197,340	222,437	188,926
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '26	Option Exercise	112.16	383	42,957	9,520	May 05
Maraldo David R.	EVP & Pres. MMD	May 02 '26	Option Exercise	112.16	552	61,912	18,371	May 05
Larson Betty D	EVP, Chief HR Officer	Apr 30 '26	Option Exercise	110.95	11,350	1,259,283	18,917	May 01
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '26	Option Exercise	110.95	464	51,481	9,296	May 01
Zachary Jennifer	EVP, General Counsel	Apr 29 '26	Option Exercise	110.03	2,951	324,699	72,351	May 01
Guindo Chirfi	EVP, Access, Policy & Comms	Apr 29 '26	Option Exercise	110.03	1,967	216,429	62,582	May 01
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 29 '26	Option Exercise	110.03	2,597	285,748	16,477	May 01
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 29 '26	Option Exercise	110.03	2,518	277,056	162,778	May 01
Williams David Michael	EVP,Chief Info&Digital Officer	Apr 29 '26	Option Exercise	110.03	1,377	151,511	32,395	May 01
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 29 '26	Option Exercise	110.03	944	103,868	9,156	May 01
Li Dean Y	Executive VP & President, MRL	Apr 29 '26	Option Exercise	110.03	4,722	519,562	96,757	May 01
Larson Betty D	EVP, Chief HR Officer	Apr 29 '26	Option Exercise	110.03	2,085	229,413	8,282	May 01
Litchfield Caroline	EVP & CFO	Apr 29 '26	Option Exercise	110.03	3,935	432,968	94,239	May 01
Davis Robert M	Chairman, CEO & President	Apr 29 '26	Option Exercise	110.03	13,300	1,463,399	456,902	May 01
Oosthuizen Johannes Jacobus	EVP, Oncology & Int?l	Apr 29 '26	Option Exercise	110.03	1,377	151,511	22,574	May 01